Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387644480> ?p ?o ?g. }
- W4387644480 endingPage "68" @default.
- W4387644480 startingPage "1" @default.
- W4387644480 abstract "Design Investigator-led, prospective, open-labelled marker-based strategy (hybrid) randomised trial. Background Allografts in 3% of kidney transplant patients fail annually. Development of antibodies against human leucocyte antigens is a validated predictive biomarker of allograft failure. Under immunosuppression is recognised to contribute, but whether increasing immunosuppression can prevent allograft failure in human leucocyte antigen Ab+ patients is unclear. Participants Renal transplant recipients > 1 year post-transplantation attending 13 United Kingdom transplant clinics, without specific exclusion criteria. Interventions Regular screening for human leucocyte antigen antibodies followed, in positive patients by interview and tailored optimisation of immunosuppression to tacrolimus, mycophenolate mofetil and prednisolone. Objective To determine if optimisation of immunosuppression in human leucocyte antigen Ab+ patients can cost-effectively prevent kidney allograft failure. Outcome Time to graft failure after 43 months follow-up in patients receiving the intervention, compared to controls, managed by standard of care. Costs and quality-adjusted life-years were used in the cost-effectiveness analysis. Randomisation and blinding Random allocation (1 : 1) to unblinded biomarker-led care or double-blinded standard of care stratified by human leucocyte antigen antibodies status (positive/negative) and in positives, presence of donor-specific antibodies (human leucocyte antigen antibodies against donor human leucocyte antigen) or not (human leucocyte antigen antibodies against non-donor human leucocyte antigen), baseline immunosuppression and transplant centre. Biomaker-led care human leucocyte antigen Ab+ patients received intervention. Human leucocyte antigen Ab-negative patients were screened every 8 months. Recruitment Began September 2013 and for 37 months. The primary endpoint, scheduled for June 2020, was moved to March 2020 because of COVID-19. Numbers randomised From 5519 screened, 2037 were randomised (1028 biomaker-led care, 1009 to standard of care) including 198 with human leucocyte antigen antibodies against donor human leucocyte antigen (106 biomaker-led care, 92 standard of care) and 818 with human leucocyte antigens antibodies against non-donor human leucocyte antigen (427 biomaker-led care, 391 standard of care). Numbers analysed Two patients were randomised in error so 2035 were included in the intention-to-treat analysis. Outcome The trial had 80% power to detect a hazard ratio of 0.49 in biomarker-led care DSA+ group, > 90% power to detect hazard ratio of 0.35 in biomarker-led care non-DSA+ group (with 5% type 1 error). Actual hazard ratios for graft failure in these biomarker-led care groups were 1.54 (95% CI: 0.72 to 3.30) and 0.97 (0.54 to 1.74), respectively. There was 90% power to demonstrate non-inferiority of overall biomarker-led care group with assumed hazard ratio of 1.4: This was not demonstrated as the upper confidence limit for graft failure exceeded 1.4: (1.02, 95% CI 0.72 to 1.44). The hazard ratio for biopsy-proven rejection in the overall biomarker-led care group was 0.5 [95% CI: 0.27 to 0.94: p = 0.03]. The screening approach was not cost-effective in terms of cost per quality-adjusted life-year. Harms No significant differences in other secondary endpoints or adverse events. Limitations Tailored interventions meant optimisation was not possible in some patients. We did not study pathology on protocol transplant biopsies in DSA+ patients. Conclusions No evidence that optimised immunosuppression in human leucocyte antigen Ab+ patients delays renal transplant failure. Informing patients of their human leucocyte antigen antibodies status appears to reduce graft rejection. Future work We need a better understanding of the pathophysiology of transplant failure to allow rational development of effective therapies. Trial registration This trial is registered as EudraCT (2012-004308-36) and ISRCTN (46157828). Funding This project was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation programme (11/100/34) and will be published in full in Efficacy and Mechanism Evaluation; Vol. 10, No. 5. See the NIHR Journals Library website for further project information." @default.
- W4387644480 created "2023-10-15" @default.
- W4387644480 creator A5000172660 @default.
- W4387644480 creator A5000891617 @default.
- W4387644480 creator A5002570839 @default.
- W4387644480 creator A5005426752 @default.
- W4387644480 creator A5008931388 @default.
- W4387644480 creator A5009032063 @default.
- W4387644480 creator A5009656263 @default.
- W4387644480 creator A5011079322 @default.
- W4387644480 creator A5017075557 @default.
- W4387644480 creator A5020532221 @default.
- W4387644480 creator A5024118354 @default.
- W4387644480 creator A5025936352 @default.
- W4387644480 creator A5026390715 @default.
- W4387644480 creator A5048054330 @default.
- W4387644480 creator A5062699494 @default.
- W4387644480 creator A5063912274 @default.
- W4387644480 creator A5065334170 @default.
- W4387644480 creator A5076417726 @default.
- W4387644480 creator A5082881613 @default.
- W4387644480 date "2023-09-01" @default.
- W4387644480 modified "2023-10-15" @default.
- W4387644480 title "Preventing kidney transplant failure by screening for antibodies against human leucocyte antigens followed by optimised immunosuppression: OuTSMART RCT" @default.
- W4387644480 cites W1486598251 @default.
- W4387644480 cites W1520683642 @default.
- W4387644480 cites W1539479843 @default.
- W4387644480 cites W1972168830 @default.
- W4387644480 cites W1980073060 @default.
- W4387644480 cites W1984812620 @default.
- W4387644480 cites W1990166011 @default.
- W4387644480 cites W1990838217 @default.
- W4387644480 cites W1994085514 @default.
- W4387644480 cites W1994412969 @default.
- W4387644480 cites W2001066085 @default.
- W4387644480 cites W2002712930 @default.
- W4387644480 cites W2030894553 @default.
- W4387644480 cites W2038981426 @default.
- W4387644480 cites W2053988935 @default.
- W4387644480 cites W2054358419 @default.
- W4387644480 cites W2067863998 @default.
- W4387644480 cites W2068064386 @default.
- W4387644480 cites W2076405972 @default.
- W4387644480 cites W2079979502 @default.
- W4387644480 cites W2087929136 @default.
- W4387644480 cites W2092409392 @default.
- W4387644480 cites W2106410556 @default.
- W4387644480 cites W2127001878 @default.
- W4387644480 cites W2131290131 @default.
- W4387644480 cites W2135370042 @default.
- W4387644480 cites W2230962694 @default.
- W4387644480 cites W2327189435 @default.
- W4387644480 cites W2526475700 @default.
- W4387644480 cites W2561211343 @default.
- W4387644480 cites W2580814825 @default.
- W4387644480 cites W2588200867 @default.
- W4387644480 cites W2757341623 @default.
- W4387644480 cites W2773812249 @default.
- W4387644480 cites W2793106936 @default.
- W4387644480 cites W2924188020 @default.
- W4387644480 cites W2966820257 @default.
- W4387644480 cites W2995906432 @default.
- W4387644480 cites W3005096260 @default.
- W4387644480 cites W3045748193 @default.
- W4387644480 cites W3083160147 @default.
- W4387644480 cites W3112530259 @default.
- W4387644480 cites W3116975117 @default.
- W4387644480 cites W4210511888 @default.
- W4387644480 cites W4210912427 @default.
- W4387644480 cites W4224243804 @default.
- W4387644480 cites W4283121935 @default.
- W4387644480 doi "https://doi.org/10.3310/kmpt6827" @default.
- W4387644480 hasPublicationYear "2023" @default.
- W4387644480 type Work @default.
- W4387644480 citedByCount "0" @default.
- W4387644480 crossrefType "journal-article" @default.
- W4387644480 hasAuthorship W4387644480A5000172660 @default.
- W4387644480 hasAuthorship W4387644480A5000891617 @default.
- W4387644480 hasAuthorship W4387644480A5002570839 @default.
- W4387644480 hasAuthorship W4387644480A5005426752 @default.
- W4387644480 hasAuthorship W4387644480A5008931388 @default.
- W4387644480 hasAuthorship W4387644480A5009032063 @default.
- W4387644480 hasAuthorship W4387644480A5009656263 @default.
- W4387644480 hasAuthorship W4387644480A5011079322 @default.
- W4387644480 hasAuthorship W4387644480A5017075557 @default.
- W4387644480 hasAuthorship W4387644480A5020532221 @default.
- W4387644480 hasAuthorship W4387644480A5024118354 @default.
- W4387644480 hasAuthorship W4387644480A5025936352 @default.
- W4387644480 hasAuthorship W4387644480A5026390715 @default.
- W4387644480 hasAuthorship W4387644480A5048054330 @default.
- W4387644480 hasAuthorship W4387644480A5062699494 @default.
- W4387644480 hasAuthorship W4387644480A5063912274 @default.
- W4387644480 hasAuthorship W4387644480A5065334170 @default.
- W4387644480 hasAuthorship W4387644480A5076417726 @default.
- W4387644480 hasAuthorship W4387644480A5082881613 @default.
- W4387644480 hasBestOaLocation W43876444801 @default.
- W4387644480 hasConcept C126322002 @default.
- W4387644480 hasConcept C147483822 @default.